Great strides have been made in recent years towards understanding the roles of natural
killer (NK) cells in immunity to tumours and viruses. NK cells are cytotoxic innate lymphoid�…

Preclinical studies of the T cell growth factor activity of IL-2 resulted in this cytokine
becoming the first immunotherapy to be approved nearly 30 years ago by the US Food and�…

Immuno-oncology is an emerging field that has revolutionized cancer treatment. Most
immunomodulatory strategies focus on enhancing T cell responses, but there has been a�…

Expansion and differentiation of antigen-experienced PD-1+ TCF-1+ stem-like CD8+ T cells
into effector cells is critical for the success of immunotherapies based on PD-1 blockade�…

Cellular therapies using regulatory T (Treg) cells are currently undergoing clinical trials for
the treatment of autoimmune diseases, transplant rejection and graft-versus-host disease. In�…

Immune checkpoint blockade (ICB) has revolutionized cancer treatment. However,
resistance to ICB occurs frequently due to tumor-intrinsic alterations or extrinsic factors in the�…

T cells and natural killer (NK) cells have complementary roles in tumor immunity, and dual T
cell and NK cell attack thus offers opportunities to deepen the impact of immunotherapy�…

Chimeric antigen receptor (CAR) T cells are ineffective against solid tumors with
immunosuppressive microenvironments. To overcome suppression, we engineered circuits�…

The metastatic spread of malignant cells to distant anatomical locations is a prominent
cause of cancer-related death. Metastasis is governed by cancer-cell-intrinsic mechanisms�…

Adoptive transfer of antigen-specific T cells represents a major advance in cancer
immunotherapy, with robust clinical outcomes in some patients. Both the number of�…